Paul R. Ortiz de Montellano, Ph.D.
Founder and Professor, University of California at San Francisco
Prof. Ortiz de Montellano is a Co-Founder of Cyterix Pharmaceuticals and is a world-renowned expert in cytochrome P450 biochemistry with more than 450 peer reviewed publications in the field. He is editor and co-author of the book “Cytochrome P450: Structure, Mechanism, and Biochemstry” currently in its third edition. Major awards include the B. B. Brodie award in Drug Metabolism of the American Society for Pharmacology and Experimental Therapeutics, the Volwiler Achievement Award of the American Association of Colleges of Pharmacy, and the RT Williams Distinguished Scientific Achievement Award of the International Society for the Study of Xenobiotics (2007). He has been on the faculty at UCSF since 1972, where he is currently Distinguished Professor, Vice-Chair of Department of Pharmaceutical Chemistry, and Associate Dean for Research of the School of Pharmacy. He was trained at MIT, Harvard, and the ETH in Zürich.
Richard Klausner, M.D.
Managing Partner, The Column Group
Dr. Klausner is the former Executive Director for Global Health of the Bill and Melinda Gates Foundation. He was the eleventh director of the National Cancer Institute between 1995 and 2001. His research has been recognized with awards including the Outstanding Investigator Award from the American Federation of Clinical Research and the William Damashek Prize for major discoveries in haematology. He received the 1997-1998 Dickson Prize in Medicine and the 1998 Raymond Bourgine Award. He has served as an Advisor to the Presidents of the Academies for counter-terrorism, and Liaison to the White House Office of Science & Technology Policy. He is a member of the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences. Dr. Klausner is a past president of the American Society of Clinical Investigation and has been Chairman of the National Science Education Standards Projects of the National Academy of Sciences.
Michael C. Venuti, Ph.D.
Dr. Venuti is a biotech industry consultant with significant expertise in drug discovery and development. He has an A.B. degree in chemistry from Dartmouth College, and a Ph.D. in synthetic organic chemistry from The Massachusetts Institute of Technology. He has had a 30-year industry career, at Syntex, Genentech and Celera in senior research management positions, then as CEO of Discovery Partners International, BioSeek, and iPierian. Dr. Venuti is a member of the Board of Directors of Infinity Pharmaceuticals, where he serves as head of the Board R&D Committee, and was Adjunct Professor of Pharmaceutical Chemistry at UCSF from 1992 through 2008. He is author on 30 primary literature papers, 9 review articles, and inventor on 26 issued US patents.
Adam R. Renslo, Ph.D.
Director of Chemistry, the SMDC, University of California at San Francisco
Dr. Renslo is a synthetic and medicinal chemist whose drug discovery experience spans target identification through candidate selection. He has been on the faculty at UCSF since 2006 and concurrently directs the chemistry efforts of the Small Molecule Discovery Center and the Sandler Center for Drug Discovery, both at UCSF. Previously, Dr Renslo held positions of increasing seniority at Vicuron Pharmaceuticals. Currently Dr Renslo’s research is focused in the areas of infectious disease and cancer and his group is also pioneering ferrous iron/heme dependent drug delivery technologies. He is author or inventor on more than 50 peer reviewed publications and patent applications and holds 8 issued US patents. Dr Renslo’s scientific training was at MIT and The Scripps Research Institute.